Dupont Capital Management Corp trimmed its holdings in Celgene Co. (NASDAQ:CELG) by 32.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 138,402 shares of the biopharmaceutical company’s stock after selling 65,732 shares during the quarter. Dupont Capital Management Corp’s holdings in Celgene were worth $8,870,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. First Mercantile Trust Co. purchased a new position in Celgene in the 4th quarter valued at $48,000. Legacy Financial Advisors Inc. grew its position in Celgene by 61.8% in the 4th quarter. Legacy Financial Advisors Inc. now owns 825 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 315 shares during the last quarter. Csenge Advisory Group purchased a new stake in shares of Celgene during the 3rd quarter worth $90,000. Global Trust Asset Management LLC boosted its position in shares of Celgene by 217.9% during the 4th quarter. Global Trust Asset Management LLC now owns 1,459 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Celgene during the 3rd quarter worth $132,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.
CELG has been the topic of several research analyst reports. Morgan Stanley decreased their target price on shares of Celgene from $93.00 to $88.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 19th. Leerink Swann set a $112.00 target price on shares of Celgene and gave the stock a “hold” rating in a research report on Friday, October 26th. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Friday, January 4th. Zacks Investment Research upgraded shares of Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 target price on the stock in a research report on Wednesday, January 23rd. Finally, ValuEngine upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Friday, January 4th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Celgene currently has an average rating of “Buy” and a consensus price target of $109.29.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.07. The business had revenue of $4.04 billion during the quarter, compared to the consensus estimate of $3.98 billion. Celgene had a return on equity of 125.35% and a net margin of 26.48%. During the same quarter in the previous year, the company posted $2.00 EPS. On average, analysts expect that Celgene Co. will post 10.01 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.com-unik.info/2019/02/09/dupont-capital-management-corp-sells-65732-shares-of-celgene-co-celg.html.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Further Reading: The risks of owning bonds
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.